EU/3/07/466: Orphan designation for the treatment of orthostatic hypotension in patients with multiple system atrophy

L-threo-3,4-dihydroxyphenylserine

Table of contents

Overview

On 2 August 2007, orphan designation (EU/3/07/466) was granted by the European Commission to The Weinberg Group LLC, United Kingdom, for L-threo-3,4-dihydroxyphenylserine for the treatment of orthostatic hypotension in patients with multiple system atrophy.

The sponsorship was transferred to The Weinberg Group Limited, United Kingdom, in March 2009, to Diamond BioPharm Limited, United Kingdom, in March 2011 and to H. Lundbeck A/S, Denmark, in December 2015.

Key facts

Active substance
L-threo-3,4-dihydroxyphenylserine
Intented use
Treatment of orthostatic hypotension in patients with multiple system atrophy
Orphan designation status
Positive
EU designation number
EU/3/07/466
Date of designation
02/08/2007
Sponsor
H. Lundbeck A/S
Ottiliavej 9
2500 Valby
Denmark
Tel. +45 4371 4270
Fax +45 4371 4274
http://www.lundbeck.com/dk/kontakt-os

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating